Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00093626 · ClinicalTrials.gov registry record · Phase 2
Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT00093626: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00093626 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 73 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00093626, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth. This phase II trial is studying how well sorafenib works in treating patients with persistent or recurrent ovarian epithelial or peritoneal cancer.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Sorafenib Tosylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2004-10 |
| Est. Completion | 2011-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00093626
The ClinicalTrials.gov registry entry for NCT00093626 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00093626 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00093626 about?
NCT00093626 is a clinical study titled "Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer". Sorafenib may stop the growth of tumor cells by stopping blood flow to the tumor and by blocking the enzymes necessary for their growth. This phase II trial is studying how well sorafenib works in treating patients with persistent or recurrent ovarian epithelial or peritoneal cancer.
What is the current status of trial NCT00093626?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2004-10. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00093626?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Sorafenib Tosylate (DRUG).
Who is sponsoring clinical trial NCT00093626?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.